Matinas BioPharma Holdings, Inc.
(NYSE Amex Equities : MTNB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -1.37%72.851.0%$2085.84m
AMGNAmgen, Inc. -0.11%198.271.3%$912.74m
REGNRegeneron Pharmaceuticals, Inc. -0.62%449.522.6%$775.54m
BIIBBiogen, Inc. -2.69%296.751.5%$711.86m
MRNAModerna, Inc. 7.55%30.050.0%$640.21m
VRTXVertex Pharmaceuticals, Inc. -3.23%217.241.9%$526.89m
ILMNIllumina, Inc. -1.96%269.053.5%$482.68m
ALXNAlexion Pharmaceuticals, Inc. -2.47%84.012.0%$265.76m
AAgilent Technologies, Inc. -3.61%71.061.6%$237.61m
EXASEXACT Sciences Corp. -4.91%57.9021.0%$205.46m
INCYIncyte Corp. -5.60%68.962.5%$167.54m
SGENSeattle Genetics, Inc. -5.92%109.276.1%$162.29m
BMRNBioMarin Pharmaceutical, Inc. -3.79%79.514.3%$160.35m
NVAXNovavax, Inc. 2.43%13.05114.7%$149.95m
CODXCo-Diagnostics, Inc. -2.66%9.150.0%$148.50m

Company Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.